Martin Zapata Laguado, Medical Oncologist and Internal Medicine Physician at the National Cancer Institute of Colombia, shared some insights from ESMO 2025 on X:
“Happy to reconnect with friends and see the exciting new advances in cancer at ESMO25. Or as the Germans say – Fangen wir an!”
“Discus trial shows that less chemotherapy and maintenance with avelumab improve QOL in countries where EV is not available in 1L presented by the Grande.”
“Promising data on GDFATHER trial in miUC and synergistic action between IO and antiGDF15 better responses than IO monoagent.”
“Confirming the importance of the multidisciplinary team (medical Oncologist) management, POTOMAC trial with positive results for DFS in nmiUC high-risk population.”
“ARASTEP trial confirms an improvement in QOL in those patients treated with triplet therapy in mHSPC fractionating docetaxel shows equivalence with the conventional dose.”
“LENCABO trial Phase 2 in mCCRCC after progression disease after anti-PD1, shows better PFS for Lenvatinib plus everolimus vs Cabozantinib with more toxicity to LENEVE.”
“OPTIC RCC trial including genomic profiles into the management of mRCC, shows that nivo cabo has a good ORR in angiogenic signatures.”
“RAMPART trial adjuvant therapy with durvalab and tremelumab positive result in DFS great benefit in highs risk patients.”
Follow the latest ESMO 2025 news on OncoDaily.